SEC filing · 8-K

Recursion Pharmaceuticals, Inc.: Material agreement

Recursion amended its master agreement with Tempus AI and licensed its TxFM RNA model to Tempus for $12,000,000.

Filed September 21, 2026

Mixed for the company

What happened

On September 15, 2026, Recursion and Tempus AI amended their master agreement to extend the term from five to six years and reduce annual license fees to $14,000,000.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Recursion Pharmaceuticals, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.